10x Genomics Shares Tumble on Fear Over Cuts to NIH
A Wednesday night earnings report left big questions about how the spending reductions would affect the company.
10x Genomics (NASDAQ:TXG) Cut to “Hold” at Leerink Partnrs
Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...
10x Genomics price target lowered to $15 from $18 at Barclays
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
Hosted on MSN8d
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.
10x Genomics Q1 EPS Estimate Decreased by Leerink Partnrs
Analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of 10x Genomics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda ...
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...
FierceBiotech11d
DNA sequencing shares slide amid 'headwinds' from Trump's NIH funding cuts
After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...
Yahoo Finance6d
10x Genomics, Inc. (TXG)
10x Genomics ( NASDAQ:TXG ) Full Year 2024 Results Key Financial Results Revenue: US$610.8m (down 1.3% from FY 2023... On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS ...
10x Genomics: Q4 Earnings Snapshot
PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had ...
10x Genomics price target lowered to $15 from $18 at TD Cowen
TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The ...